ROUX DAVID J
Known title: DirectorCIK: 0001234273
Associated companies
Transaction History
| BSX | ▲ Buy | Grant | 3,946 | $0 | 5/4/2023 | View on chart |
| BSX | ▲ Buy | Grant | 4,877 | $0 | 5/5/2022 | View on chart |
| BSX | ▲ Buy | Grant | 3,946 | $0 | 5/4/2023 | View on chart |
| BSX | ▲ Buy | Grant | 4,877 | $0 | 5/5/2022 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Boston Scientific (BSX) Faces Catheter Recall Amid Valuation Debate
Boston Scientific announced a recall of 262,686 catheters because of a life‑threatening tip failure risk. The recall adds pressure as analysts note the company needs clear evidence of its turnaround to justify a better valuation. Truist Securities kept its rating but cut its price target to $51, reflecting a more cautious view. The stock has still moved higher than the broader market, indicating mixed investor reactions.
Boston Scientific (BSX) Faces Catheter Recall Amid Valuation Debate. Boston Scientific announced a recall of 262,686 catheters because of a life‑threatening tip failure risk. The recall adds pressure as analysts note the company needs clear evidence of its turnaround to justify a better valuation. Truist Securities kept its rating but cut its price target to $51, reflecting a more cautious view. The stock has still moved higher than the broader market, indicating mixed investor reactions.